1. Home
  2. BLMN vs KROS Comparison

BLMN vs KROS Comparison

Compare BLMN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLMN

Bloomin' Brands Inc.

HOLD

Current Price

$6.23

Market Cap

569.7M

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$16.57

Market Cap

584.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLMN
KROS
Founded
1988
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
569.7M
584.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
BLMN
KROS
Price
$6.23
$16.57
Analyst Decision
Hold
Buy
Analyst Count
8
9
Target Price
$8.50
$23.00
AVG Volume (30 Days)
2.4M
266.1K
Earning Date
02-25-2026
03-03-2026
Dividend Yield
7.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.57
Revenue
$3,952,793,000.00
$246,718,000.00
Revenue This Year
$2.19
$6,924.79
Revenue Next Year
$0.35
N/A
P/E Ratio
$16.77
$10.53
Revenue Growth
7.72
37798.31
52 Week Low
$5.86
$9.12
52 Week High
$12.47
$22.55

Technical Indicators

Market Signals
Indicator
BLMN
KROS
Relative Strength Index (RSI) 45.52 36.19
Support Level $6.37 $16.31
Resistance Level $7.36 $17.17
Average True Range (ATR) 0.39 0.63
MACD 0.00 -0.13
Stochastic Oscillator 44.00 18.26

Price Performance

Historical Comparison
BLMN
KROS

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabba's. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S., while restaurants operating outside the U.S. are included in the international segment.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: